Moreover, CD133 was reported to be a necessary factor for GBM cells to adapt to conventional therapies (radio- and chemotherapy), migrate between different clonal populations of tumors, and re-emerge to initiate tumor relapse. The gene discussed is PROM1; the disease is glioblastoma.